Rena Conti is an Associate Professor of Markets, Public Policy and Law at Questrom School of Business, Boston University and co-Director of the Technology Policy and Research Initiative at Boston University Questrom School of Business and Law School. Professor Conti holds a Ph.D. from Harvard University Graduate School of Arts and Sciences in health policy and economics. She was faculty at The University of Chicago between 2006 and 2018. Professor Conti is an internationally recognized expert in the fields of health policy, economics, and the biopharmaceutical industry. She has published extensively on prescription drug pricing, utilization, spending, competition, and innovation. Professor Conti has testified on the economics of prescription drugs in hearings held by the U.S. Senate, the U.S. House of Representatives, the U.S. Food and Drug Administration, the Federal Trade Commission and numerous state legislative houses. Professor Conti served as Special Government Advisor to the Centers for Medicare and Medicaid Services (CMS) 2022-2023 and held additional advisory roles at the U.S. Food and Drug Administration (FDA).
Professor Conti serves as the lead economist on the State of Louisiana’s landmark Subscription Model for Hepatitis C Virus Elimination (Hepfreela). The research of Professor Conti has been featured in The New York Times, Wall Street Journal, Washington Post, Bloomberg News, USA Today, the Chicago Tribune, Boston Globe, LA Times, 60 Minutes, the Daily Show, Vox, The Atlantic, Statnews, and The Colbert Report, among other print and media outlets. Grants and awards from the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Science Foundation, the Sloan Foundation, the Commonwealth Fund, American Cancer Society, and Arnold Ventures, among other sources, support the research of Professor Conti.